China’s MOH Further Standardizes Centralized Drug Purchase Online
This article was originally published in PharmAsia News
Executive SummaryChina's Ministry of Health and five other state agencies recently signed an opinion draft on further standardizing centralized drug purchases in heath care institutions. According to the document, online centralized drug purchase implementation will be led by the government, with each province (including autonomous regions and municipalities) as a purchasing unit. To reduce drug distribution costs, pharmaceutical manufacturers will now be the direct bidders instead of drug wholesalers. Industry analysts believe that the policy will facilitate the establishment of a new drug purchase and sales system: first, market focus of drug manufacturing will be heightened; the drug distribution structure will change, as will sales patterns of prescription drugs. However, analysts think these will have little impact on the current drug agent model. (Click here for more - Chinese Language)
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.